Travere Therapeutics (TVTX) FCF Margin (2014 - 2026)
Travere Therapeutics (TVTX) posted FCF Margin of 31.73% for Q1 2026, down 83.96% on a QoQ basis from 17.25% in Q4 2025, and up 1989.0% year-over-year from 1.52% in Q1 2025.
Travere Therapeutics (TVTX) FCF Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics' FCF Margin history runs 13 years deep, the most recent figure standing at 31.73% for Q1 2026.
- Quarterly FCF Margin rose 1989.0% year-over-year to 31.73% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 56.32% (up 249.0% YoY) and the FY2025 annual result came in at 406.28%, up 50812.0% from the prior year.
- FCF Margin was 31.73% for Q1 2026 at Travere Therapeutics, down from 17.25% in the prior quarter.
- Across five years, FCF Margin topped out at 35.44% in Q3 2025 and bottomed at 321.42% in Q1 2023.
- A 5-year average of 125.26% and a median of 128.6% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 24225 bps — and 2025, when it surged 23576 bps.
- Travere Therapeutics' FCF Margin stood at 186.34% in 2022, then plunged by 38 bps to 257.07% in 2023, then surged by 81 bps to 48.25% in 2024, then surged by 64 bps to 17.25% in 2025, then plunged by 84 bps to 31.73% in 2026.
- Business Quant data shows TVTX's FCF Margin at 31.73% in Q1 2026, 17.25% in Q4 2025, and 35.44% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -31.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.73% |
| Dec 31, 2025 | -17.25% |
| Sep 30, 2025 | 35.44% |
| Jun 30, 2025 | 4.35% |
| Mar 31, 2025 | -51.62% |
| Dec 31, 2024 | -48.25% |
| Sep 30, 2024 | -67.01% |
| Jun 30, 2024 | -74.71% |
| Mar 31, 2024 | -287.38% |
| Dec 31, 2023 | -257.07% |
| Sep 30, 2023 | -159.44% |
| Jun 30, 2023 | -160.79% |
| Mar 31, 2023 | -321.42% |
| Dec 31, 2022 | -186.34% |
| Sep 30, 2022 | -140.83% |
| Jun 30, 2022 | -128.60% |
| Mar 31, 2022 | -236.85% |
| Dec 31, 2021 | 55.91% |
| Sep 30, 2021 | 46.49% |
| Jun 30, 2021 | 11.71% |